Acanthosis nigricans-like hyperpigmentation secondary to triazinate therapy.
Cutaneous hyperpigmentation resembling acanthosis nigricans developed in two patients with malignant brain tumors following chemotherapy with triazinate (Baker's Antifol), a folic acid antagonist. In both cases, the eruption resolved after the cessation of drug administration and reappeared after the reinstitution of triazinate therapy. A skin biopsy specimen from one patient showed microscopic changes consistent with those found in acanthosis nigricans. The other patient had a decreased serum folate level that returned to normal as the hyperpigmentation resolved. Folate may have a role in triazinate-induced acanthosislike hyperpigmentation.
D000052:Acanthosis Nigricans / Q000175:diagnosis; D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D008297:Male; D010859:Pigmentation Disorders / Q000139:chemically induced* / Q000175:diagnosis / Q000473:pathology; D012867:Skin / Q000473:pathology; D014227:Triazines / Q000009:adverse effects*
D000970:Antineoplastic Agents; D014227:Triazines; C012071:triazinate